



Specimen Collection Date: DD / MMM / YYYY

## Patient Information

Last Name \_\_\_\_\_

First Name \_\_\_\_\_

Date of Birth DD / MMM / YYYY Sex:  Male  Female

MRN \_\_\_\_\_

Address \_\_\_\_\_

City \_\_\_\_\_

State \_\_\_\_\_ Zip code \_\_\_\_\_

Phone \_\_\_\_\_

I understand that I will be responsible for the amount of \$249 related to the services provided to me by GeneType. I understand that the charges presented to me are due in full within 30 days of service. I also understand that this charge is an elective service and only administered by a licensed healthcare provider. I certify that I have agreed to the forgoing, and I am the patient, the patient's representative or duly authorized by the patient as the patient's general agent to execute the above and accept its terms.

Patient Signature \_\_\_\_\_

Date DD / MMM / YYYY

Diagnosis (ICD-10) Code: \_\_\_\_\_

## Ordering Healthcare Provider Information

Last Name \_\_\_\_\_

First Name \_\_\_\_\_

Practice/Institution Name \_\_\_\_\_

Office Contact \_\_\_\_\_

Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_

Zip code \_\_\_\_\_ NPI Number \_\_\_\_\_

Phone \_\_\_\_\_ Fax \_\_\_\_\_

Email \_\_\_\_\_

Your signature constitutes a certification of Medical Necessity and implies consent for genetic testing to be performed with a signed consent form on file. To be medically necessary, tests must be ordered by a treating healthcare provider (or their authorized representative) who provides a consultation or treats a patient for specific medical problems and uses findings in the management of the patient.

Healthcare Provider Signature \_\_\_\_\_

Date DD / MMM / YYYY

## Patient Clinical Information Responses to all questions required

1. Does the patient have a medical history of any breast cancer or ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS)? Yes / No  
*If yes, the patient does not qualify for this test.*

2. Does the patient have a mutation in either the BRCA1 or BRCA2 gene, or a diagnosis of a genetic syndrome that may be associated with elevated risk of breast cancer? If yes, the patient does not qualify for this test. Yes / No

3. What is the patient's age? This test is valid for patients aged 35 to 80 years. Age: \_\_\_\_\_

4. What is the patient's race/ethnicity? If other, patient does not qualify for test. See note below.  
 Caucasian  African American  
 Hispanic  Other

5. How many first-degree relatives have been diagnosed with breast cancer (mother, sisters, daughters)? Number: \_\_\_\_\_  
 Unknown

6. What was the age of the youngest first-degree relative when they were diagnosed with breast cancer? Age: \_\_\_\_\_  
 Unknown

7. How many second-degree relatives have been diagnosed with breast cancer (aunts, nieces, grandparents, grandchildren, half-siblings, and double cousins)? Number: \_\_\_\_\_  
 Unknown

8. What is the patient's height? Feet: \_\_\_\_\_ Inches: \_\_\_\_\_

9. What is the patient's weight? Pounds: \_\_\_\_\_

10. What is the patient's menopausal status?  
 Pre-/Peri-menopausal  Post-menopausal  Unknown

11. Has the patient ever had a breast mammogram? Yes / No

12. What was the patients' reported mammographic breast density?  
 \_\_\_ % Density (preferred) (OR)  
 Bi-Rads a  Bi-Rads b  Bi-Rads c  Bi-Rads d  
 (OR)  Unknown

\*Bi-Rads is a registered trademark of the American College of Radiology (ACR) and utilizes the following breast composition definitions: Bi-Rads a: fatty; Bi-Rads b: scattered density; Bi-Rads c: heterogeneously dense; Bi-Rads d: extremely dense. GeneType is independently owned and operated and is not an affiliate of the ACR.

Internal Use Only  
Date / Time Stamp

Place Barcode here

NOTE: GeneType for Breast Cancer is currently validated in women 35 years or older of Caucasian descent. The risk model incorporates ethnicity-specific polygenic risk scores and population incidence data for patients of African American and Hispanic American descent derived from the Surveillance, Epidemiology, and End Results Program (SEER), however, the model has not been validated in these populations as yet.